Sarcospan Expression for Muscular Dystrophy Adhesion Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for muscular dystrophy, such as corticosteroids and exon skipping therapies, are insufficient in slowing disease progression and are only applicable to a limited percentage of patients, highlighting the need for more robust treatments.
Innovation Solution
A compound that increases the expression of sarcospan, a transmembrane protein associated with adhesion complexes, is used to treat or prevent muscular dystrophy by enhancing membrane stability and adhesion complex function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If corticosteroids are used to treat muscular dystrophy, then inflammation is dampened and ambulation is extended by several years, but adhesion complex and membrane stability deficiencies are not addressed
Solution Approach 1:
The patent introduces sarcospan as an intermediary protein that mediates between the dystrophin-glycoprotein complex and the extracellular matrix. By increasing sarcospan expression, the invention strengthens the link between muscle fibers and the extracellular matrix, directly addressing the adhesion complex stability deficiency that corticosteroids fail to address.
Solution Approach 2:
The invention changes the expression level parameter of sarcospan from normal to increased. By manipulating this biological parameter through compound administration, the patent enhances membrane stability and adhesion complex function, providing a mechanism that complements or exceeds corticosteroid effects.
2Quantity of substance
If eteplirsen is used to increase truncated dystrophin protein production, then exon skipping therapy is applied, but it is only applicable to approximately 14% of DMD patients with mutations amenable to exon 51 skipping
Solution Approach 1:
The patent makes the treatment approach universal by targeting sarcospan, a protein that is constitutively expressed in all muscle tissues regardless of the specific dystrophin mutation type. This allows the same therapeutic mechanism to benefit a broader range of patients beyond the 14% who can receive eteplirsen, addressing the versatility limitation of exon skipping therapy.
Solution Approach 2:
Instead of attempting to restore the defective dystrophin protein through exon skipping, the invention uses sarcospan as a functional copy or surrogate that performs the adhesion function normally associated with dystrophin. This alternative approach bypasses the need for dystrophin-specific mutations to be amenable to skipping.
3Ease of operation
If existing FDA approved drugs are used for DMD, then some symptom management is achieved, but they are not sufficient to substantially slow disease progression
Solution Approach 1:
The invention takes preliminary action by increasing sarcospan expression before significant muscle degradation occurs. By pre-strengthening the adhesion complexes and membrane stability through sarcospan upregulation, the patent creates a protective foundation that slows disease progression rather than merely managing symptoms after damage has occurred.
Solution Approach 2:
The patent creates a composite functional system by combining sarcospan with the existing dystrophin-glycoprotein complex. This composite structure enhances the overall mechanical and adhesive properties of the muscle membrane, providing a more robust protective effect than single-component treatments like corticosteroids.
Data Source
Figure 1a~1j
Figure 2
Figure 3
AI summary
Provided herein are methods for treating and preventing a disease related to diminution or dysfunction of a dystrophin-related complex in a subject in need thereof, comprising administering to the subject a compound that increases sarcospan. Also provided herein are pharmaceutical compositions comprising a compound that increases sarcospan, or a pharmaceutically acceptable salt or ester thereof, useful for the treatments described herein.